文献速递眼底病与葡萄膜炎

δ阿片受体激动可保留实验性糖尿病视网膜色素上皮细胞紧密连接并改善视网膜病变

δ Opioid Receptor Agonism Preserves the Retinal Pigmented Epithelial Cell Tight Junctions and Ameliorates the Retinopathy in Experimental Diabetes.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2019-01-01

研究在链脲佐菌素(CL57B)糖尿病小鼠中玻璃体腔注射shRNA-DOR(108 TU/mL)并给予或不给予δ阿片受体激动剂表儿茶素(饮水0.05 g/只/天)16周,评估视网膜病变早期标志物与紧密连接蛋白。结果显示DOR激动可防止胶质纤维酸性蛋白、VEGF上调及色素上皮衍生因子、occludin、claudin-1、闭锁小带蛋白-1下调,DOR沉默部分取消表儿茶素的保护作用;人视网膜标本中DOR分布相似。作者认为DOR激动保留RPE紧密连接并减少糖尿病视网膜病变早期标志物,DOR可能是治疗糖尿病视网膜病变并保留RPE紧密连接蛋白的潜在治疗靶点。

要点

  • DOR激动剂表儿茶素可防止糖尿病小鼠视网膜胶质纤维酸性蛋白和VEGF上调。
  • DOR激动剂可防止色素上皮衍生因子、occludin、claudin-1和闭锁小带蛋白-1下调。
  • 视网膜DOR沉默部分取消表儿茶素的保护作用。

核心结论

  • 实验强烈提示DOR激动保留RPE紧密连接并减少糖尿病模型视网膜病变早期标志物。
  • 作者认为这些新发现将DOR指定为治疗糖尿病视网膜病变并保留RPE紧密连接蛋白的潜在治疗工具。

研究设计与样本

  • 在CL57B糖尿病小鼠中玻璃体腔注射shRNA-DOR(108 TU/mL),给予或不给予DOR激动剂表儿茶素(饮水0.05 g/只/天)16周,评估视网膜病变标志物和视网膜外紧密连接蛋白。
  • 同时评估糖尿病和非糖尿病供者死后人视网膜中DOR的存在。

主要发现

  • DOR存在于RPE层和神经视网膜。
  • 表儿茶素治疗防止视网膜病变早期标志物胶质纤维酸性蛋白和VEGF上调,并防止色素上皮衍生因子、occludin、claudin-1和闭锁小带蛋白-1紧密连接表达下调。
  • 糖尿病小鼠视网膜中DOR沉默部分取消表儿茶素的保护作用。
  • 人视网膜标本中DOR遍布视网膜,非糖尿病和糖尿病供者相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Outer blood retinal barrier breakdown is a neglected feature of diabetic retinopathy (DR). We demonstrated that the agonism of the δ opioid receptor (DOR) by epicatechin preserves the tight junction proteins in ARPE-19 cells under diabetic conditions. Presently, we aimed to evaluate the possible role of the DOR on the maintenance of tight junction of RPE layer and on the early markers of experimental DR. METHODS: DR markers and external retinal tight junction proteins were evaluated in CL57B diabetic mice submitted to intravitreous injection of short hairpin RNA (shRNA)-DOR (108 transducing units [TU]/mL) treated or not with DOR agonist (0.05 g/animal/d of epicatechin in drinking water) for 16 weeks. The presence of DOR in human retina from postmortem eyes from diabetic and nondiabetic donors were also performed. RESULTS: DOR is present in RPE layer and in neuro retina. The treatment with DOR agonist prevented the upregulation of the early markers of retinopathy (glial fibrillary acidic protein, VEGF) and the downregulation of pigment epithelium-derived factor, occludin, claudin-1, and zonula occludens-1 tight junction expressions. The silencing of DOR in retina of diabetic mice partially abolished the protective effects of epicatechin. In human retina specimens, DOR is present throughout the retina, similarly in nondiabetic and diabetic donors. CONCLUSIONS: This set of experiments strongly indicates that the DOR agonism preserves RPE tight junctions and reduces the early markers of retinopathy in model of diabetes. These novel findings designate DOR as a potential therapeutic tool to treat DR with preservation of the RPE tight junction proteins.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Lopes de Faria JM, Duarte DA, Simó R, et al. δ Opioid Receptor Agonism Preserves the Retinal Pigmented Epithelial Cell Tight Junctions and Ameliorates the Retinopathy in Experimental Diabetes. Invest Ophthalmol Vis Sci. 2019. PMID: 31529081. doi:10.1167/iovs.19-26761

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。